Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies

Thrombosis Research

Volumn 122, Issue 5, 2008, Pages 584-598

  ten Cate Hoek, Arina J ^a,b   Prins, Martin H ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; COUMARIN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO;

BLEEDING; CANCER PATIENT; CLINICAL PROTOCOL; DRUG EFFICACY; DRUG INDICATION; HUMAN; HYPERCOAGULABILITY; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; METASTASIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SURVIVAL TIME; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 49549102055     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.026     Document Type: Review

References (105)

1. Silverstein M.D., Heit J.A., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 6 (Mar 23 1998) 585-593
2. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 6 (Mar 27 2000) 809-815
3. Levitan N., Dowlati A., Remick S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 78 5 (Sep 1999) 285-291 [Baltimore]
4. Blom J.W., Doggen C.J., Osanto S., and Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 6 (Feb 9 2005) 715-722
5. Sorensen H.T., Mellemkjaer L., Olsen J.H., and Baron J.A. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343 25 (Dec 21 2000) 1846-1850
6. Liebman H.A. Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control 12 Suppl 1 (Sep 2005) 11-16 [Review]
7. Levine M. Low-molecular-weight heparin or oral anticoagulation for secondary prevention of deep vein thrombosis in cancer patients. Semin Thromb Hemost 29 Suppl 1 (Dec 2003) 9-11 [Review]
8. Lee A.Y. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 110 4 (Jun 1 2003) 167-172 [Review]
9. Mandala M., Ferretti G., Cremonesi M., Cazzaniga M., Curigliano G., and Barni S. Venous thromboembolism and cancer: new issues for an old topic. Crit Rev Oncol Hematol 48 1 (Oct 2003) 65-80 [Review]
10. Levine M.N. Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 28 3 (Jun 2002) 145-149 [Review]
11. Kher A., and Samama M.M. Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists. J Thromb Haemost 3 3 (Mar 2005) 473-481 [Review]
12. Kakkar A.K. Low-molecular-weight heparin and survival in patients with malignant disease. Cancer Control 12 Suppl 1 (Sep 2005) 22-30 [Review]
13. Zacharski L.R., Prandoni P., and Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 10 1 (Jan 2005) 72-79 [Review]
14. Khushal A., Quinlan D., Alikhan R., Gardner J., Bailey C., and Cohen A. Thromboembolic disease in surgery for malignancy-rationale for prolonged thromboprophylaxis. Semin Thromb Hemost 28 6 (Dec 2002) 569-576 [Review]
15. Falanga A., and Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management. Ann Oncol 16 5 (May 2005) 696-701
16. Heit J.A. Cancer and venous thromboembolism: scope of the problem. Cancer Control 12 Suppl 1 (Sep 2005) 5-10 [Review]
17. Thodiyil P., and Kakkar A.K. Can low-molecular-weight heparins improve outcome in patients with cancer?. Cancer Treat Rev 28 3 (Jun 2002) 151-155 [Review]
18. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell Jr. C.J., Forcier R.J., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 53 10 (May 15 1984) 2046-2052
19. Smorenburg S.M., Vink R., Otten H.M., Swaneveld F., and Buller H.R. The effects of vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost 86 6 (Dec 2001) 1586-1587 [Review]
20. Miller G.J., Bauer K.A., Howarth D.J., Cooper J.A., Humphries S.E., and Rosenberg R.D. Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. J Thromb Haemost 2 12 (Dec 2004) 2107-2114
21. Lee A.Y. Cancer and thromboembolic disease: pathogenic mechanisms. Cancer Treat Rev 28 3 (Jun 2002) 137-140 [Review]
22. Falanga A., Barbui T., Rickles F.R., and Levine M.N. Guidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. Thromb Haemost 70 3 (Sep 1 1993) 540-542
23. Thompson C.M., and Rodgers L.R. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 223 5 (May 1952) 469-478
24. Peuscher F.W. Thrombosis and bleeding in cancer patients. Neth J Med 24 1 (1981) 23-35
25. Schulman S., Rhedin A.S., Lindmarker P., Carlsson A., Larfars G., Nicol P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332 25 (Jun 22 1995) 1661-1665
26. Baron J.A., Gridley G., Weiderpass E., Nyren O., and Linet M. Venous thromboembolism and cancer. Lancet 351 9109 (Apr 11 1998) 1077-1080
27. [Erratum in]. Lancet 355 9205 (Feb 26 2000) 758
28. Nordstrom M., Lindblad B., Anderson H., Bergqvist D., and Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 308 6933 (Apr 2 1994) 891-894
29. Kakkar A.K., and Williamson R.C. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 25 2 (1999) 239-243 [Review]
30. Clagett G.P., Anderson Jr. F.A., Geerts W., Heit J.A., Knudson M., Lieberman J.R., et al. Prevention of venous thromboembolism. Chest 114 5 Suppl (Nov 1998) 531S-560S [Review]
31. Arnold D.M., Kahn S.R., and Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest 120 6 (Dec 2001) 1964-1971
32. Kakkar A.K., Levine M., Pinedo H.M., Wolff R., and Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 8 4 (2003) 381-388
33. Lieberman M.A. Relationship of mortality rates to entrance to a home for the aged. Geriatrics 16 (Oct 1961) 515-519
34. Sack Jr. G.H., Levin J., and Bell W.R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56 1 (Jan 1977) 1-37
35. Horton J. Venous thrombotic events in cancer: the bottom line. Cancer Control 12 Suppl 1 (Sep 2005) 31-37 [Review]
36. Geerts W.H., Pineo G.F., Heit J.A., Bergqvist D., Lassen M.R., Colwell C.W., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 338S-400S [Review]
37. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., Girolami B., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100 10 (Nov 15 2002) 3484-3488
38. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., and Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 18 17 (Sep 2000) 3078-3083
39. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 204S-233S
40. [Erratum in]. Chest 127 1 (Jan 2005) 415-416
41. Prandoni P., Lensing A.W., and Prins M.H. The natural history of deep-vein thrombosis. Semin Thromb Hemost 23 2 (1997) 185-188 [Review]
42. Buller H.R., Agnelli G., Hull R.D., Hyers T.M., Prins M.H., and Raskob G.E. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (Sep 2004) 401S-428S [Review]
43. [Erratum in]. Chest 127 1 (Jan 2005) 416
44. Luk C., Wells P.S., Anderson D., and Kovacs M.J. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 111 4 (Sep 2001) 270-273
45. Prins M.H., Hutten B.A., Koopman M.M., and Buller H.R. Long-term treatment of venous thromboembolic disease. Thromb Haemost 82 2 (Aug 1999) 892-898 [Review]
46. Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., and Goldhaber S.Z. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 7 (Aug 17 2004) 874-879
47. Cohen A.T., Davidson B.L., Gallus A.S., Lassen M.R., Prins M.H., Tomkowski W., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332 7537 (Feb 11 2006) 325-329
48. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341 11 (Sep 9 1999) 793-800
49. Alikhan R., Cohen A.T., Combe S., Samama M.M., Desjardins L., Eldor A., et al. MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 164 9 (May 10 2004) 963-968
50. Goldhaber S.Z., Dunn K., and MacDougall R.C. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 118 6 (Dec 2000) 1680-1684
51. Rashid S.T., Thursz M.R., Razvi N.A., Voller R., Orchard T., Rashid S.T., et al. Venous thromboprophylaxis in UK medical inpatients. J R Soc Med 98 11 (Nov 2005) 507-512
52. Zangari M., Barlogie B., Anaissie E., Saghafifar F., Eddlemon P., Jacobson J., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 5 (Sep 2004) 715-721
53. Levine M., Hirsh J., Gent M., Arnold A., Warr D., Falanga A., et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 8902 (Apr 9 1994) 886-889
54. Lee A.Y. Epidemiology and management of venous thromboembolism in patients with cancer. Thromb Res 110 4 (Jun 1 2003) 167-172 [Review]
55. Geerts W.H., Heit J.A., Clagett G.P., Pineo G.F., Colwell C.W., Anderson Jr. F.A., et al. Prevention of venous thromboembolism. Chest 119 1 Suppl (Jan 2001) 132S-175S [Review]
56. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 84 8 (Aug 1997) 1099-1103
57. McLeod R.S., Geerts W.H., Sniderman K.W., Greenwood C., Gregoire R.C., Taylor B.M., et al. Canadian Colorectal Surgery DVT Prophylaxis Trial investigators. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the Canadian Colorectal DVT Prophylaxis Trial: a randomized, double-blind trial. Ann Surg 233 3 (Mar 2001) 438-444
58. Agnelli G., Bergqvist D., Cohen A.T., Gallus A.S., Gent M., and PEGASUS investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 92 10 (Oct 2005) 1212-1220
59. Simonneau G., Laporte S., Mismetti P., Derlon A., Samii K., Samama C.M., et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. J Thromb Haemost 4 8 (Aug 2006) 1693-1700
60. Oates-Whitehead R.M., D'Angelo A., and Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev 4 (2003) CD003679 [Review]
61. Marras L.C., Geerts W.H., and Perry J.R. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 89 3 (Aug 1 2000) 640-646 [Review]
62. Nurmohamed M.T., van Riel A.M., Henkens C.M., Koopman M.M., Que G.T., d'Azemar P., et al. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 75 2 (Feb 1996) 233-238
63. Agnelli G., Piovella F., Buoncristiani P., Severi P., Pini M., D'Angelo A., et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 339 2 (Jul 9 1998) 80-85
64. Macdonald R.L., Amidei C., Baron J., Weir B., Brown F., Erickson R.K., et al. Randomized, pilot study of intermittent pneumatic compression devices plus dalteparin versus intermittent pneumatic compression devices plus heparin for prevention of venous thromboembolism in patients undergoing craniotomy. Surg Neurol 59 5 (May 2003) 363-372 [discussion 372-4]
65. Goldhaber S.Z., Dunn K., Gerhard-Herman M., Park J.K., and Black P.M. Low rate of venous thromboembolism after craniotomy for brain tumor using multimodality prophylaxis. Chest 122 6 (Dec 2002) 1933-1937
66. Iorio A., and Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 160 15 (Aug 14-28 2000) 2327-2332
67. Carman T.L., Kanner A.A., Barnett G.H., and Deitcher S.R. Prevention of thromboembolism after neurosurgery for brain and spinal tumors. South Med J 96 1 (Jan 2003) 17-22
68. Mismetti P., Laporte S., Darmon J.Y., Buchmuller A., and Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88 7 (Jul 2001) 913-930
69. Bergqvist D., Agnelli G., Cohen A.T., Eldor A., Nilsson P.E., Le Moigne-Amrani A., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 13 (Mar 28 2002) 975-980
70. Rasmussen M.S., et al., on behalf of the FAME investigators. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a Multicenter Randomised Open Label Study. J Thromb Haemost (Aug 1 2006) [Epub ahead of print]
71. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., Levine M., Prins M.H., and Buller H.R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 82 2 (Aug 1999) 947-952
72. van Der Heijden J.F., Hutten B.A., Buller H.R., and Prins M.H. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 4 (2000) CD002001 [Review]
73. [Update in]. Cochrane Database Syst Rev 1 (2002) CD002001
74. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (Jul 10 2003) 146-153
75. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 15 (Aug 12-26 2002) 1729-1735
76. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., van der Meer J., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334 11 (Mar 14 1996) 682-687
77. [Erratum in]. N Engl J Med 337 17 (Oct 23 1997) 1251
78. Levine M., Gent M., Hirsh J., Leclerc J., Anderson D., Weitz J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334 11 (Mar 14 1996) 677-681
79. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 337 10 (Sep 4 1997) 657-662
80. Merli G., Spiro T.E., Olsson C.G., Abildgaard U., Davidson B.L., Eldor A., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 134 3 (Feb 6 2001) 191-202
81. Rickles F.R., and Edwards R.L. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 62 1 (Jul 1983) 14-31
82. Prandoni P., Lensing A.W., Buller H.R., Carta M., Cogo A., Vigo M., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339 8791 (Feb 22 1992) 441-445
83. Schulman S., and Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. N Engl J Med 342 26 (Jun 29 2000) 1953-1958
84. Smorenburg S.M., Hettiarachchi R.J., Vink R., and Buller H.R. The effects of unfractionated heparin on survival in patients with malignancy-a systematic review. Thromb Haemost 82 6 (Dec 1999) 1600-1604
85. Lebeau B., Chastang C., Brechot J.M., Capron F., Dautzenberg B., Delaisements C., et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites Cellules" Group. Cancer 74 1 (Jul 1 1994) 38-45
86. Moyano A.J., Gonzalez-Martin A., Fernandez E., et al. Weekly docetaxel (D) and a short course of estramustine phosphate (EMO) with subcutaneous heparin low molecular weight in hormone resistant prostate cancer (HRPR);an active regimen without thrombosis related events. Proc Am Soc Clin Oncol 22 (2004) 436
87. Wojtukiewicz M.Z., Kozlowski L., Ostrowska K., Dmitruk A., and Zacharski L.R. Low molecular weight heparin treatment for malignant melanoma: a pilot clinical trial. Thromb Haemost 89 2 (Feb 2003) 405-407
88. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., and Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130 10 (May 18 1999) 800-809
89. Ferretti G., Bria E., Giannarelli D., Carlini P., Felici A., Mandala M., et al. Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?. J Clin Oncol 23 28 (Oct 1 2005) 7248-7250
90. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2 8 (Aug 2004) 1266-1271
91. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22 10 (May 15 2004) 1944-1948
92. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23 10 (Apr 1 2005) 2130-2135
93. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 10 (Apr 1 2005) 2123-2129
94. Conti S, Guercini F, Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1726 patients treated for at least three months. Pathophysiol Haemost Thromb. 2003 Jul-2004 Aug;33(4):197-201.
95. Prandoni P., Falanga A., and Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 6 6 (Jun 2005) 401-410 [Review]
96. Folkman J., Langer R., Linhardt R.J., Haudenschild C., and Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221 4612 (Aug 19 1983) 719-725
97. Zaharski L.R., and Donati M.B. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy. Thromb Haemost 61 3 (Jun 30 1989) 526-528
98. Falanga A. The effect of anticoagulant drugs on cancer. J Thromb Haemost 2 8 (Aug 2004) 1263-1265
99. Ruf W., and Mueller B.M. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32 Suppl 1 (Apr 2006) 61-68 [Review]
100. Kakkar A.K. Low-and ultra-low-molecular-weight heparins. Best Pract Res Clin Haematol 17 1 (Mar 2004) 77-87 [Review]
101. Collen A., Smorenburg S.M., Peters E., Lupu F., Koolwijk P., Van Noorden C., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60 21 (Nov 1 2000) 6196-6200
102. Nakajima M., Irimura T., and Nicolson G.L. Heparanases and tumor metastasis. J Cell Biochem 36 2 (Feb 1988) 157-167 [Review]
103. Rak J., and Weitz J.I. Heparin and angiogenesis: size matters!. Arterioscler Thromb Vasc Biol 23 11 (Nov 1 2003) 1954-1955
104. Khorana A.A., Sahni A., Altland O.D., and Francis C.W. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 23 11 (Nov 1 2003) 2110-2115
105. Sylvester D.M., Liu S.Y., and Meadows G.G. Augmentation of antimetastatic activity of interferon and tumor necrosis factor by heparin. Immunopharmacol Immunotoxicol 12 2 (1990) 161-180